A possible new front runner is emerging in the drug war against chronic myeloid leukemia ( CML ). While still considered experimental, this drug is showing itself to be a powerful agent against advanced forms of the disease.

Gleevec ( imatinib ) has transformed the treatment of chronic myeloid leukemia ( CML ). The problem is, this drug stops working at some point in many patients. A drug under development, combined with another currently available medication, may offer patients new options.

It doesn't happen commonly, though some diseases can present themselves as other diseases. Scientists now know this sometimes happens with two forms of leukemia.

It's well known that cancer can be passed between a donor and recipient during a transplant operation. One such exchange has actually advanced the scientific understanding of lymphoma.

It's the most aggressive blood cancer. Unfortunately, Diffuse Large B-Cell Lymphoma ( DLBCL ) is also the most common form of lymphoma in adults. But there is some good news - researchers may have a new target for treating this disease.

Chronic Myeloid Leukemia ( CML ) has some amazing treatment options for patients. The disease has proven to respond well to three drugs known as tyrosine kinase inhibitors. An ongoing trial is looking to see which of two of these drugs is most effective.

Since its introduction some years ago, Gleevec ( imatinib ) has been the drug of choice for treating patients newly diagnosed with chronic myeloid leukemia ( CML ).

Everything ages over time. And human stem cells are no exception. Understanding this aging process may help explain why the elderly are more susceptible to infections and certain cancers.

Research into more effective treatments for chronic myeloid leukemia is opening up all sorts of possibilities. Drugs are being combined, new drugs are being developed and there is even work involving a possible vaccine.

The outlook for people with chronic myeloid leukemia has improved by leaps and bounds in recent years. A number of medications are now keeping the disease under wraps.